← Back to patent-cliff list
CAS 926038-16-6
4-methyl-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzoic acid
Codes: RADO-005
Application context (from source-drug indications)
Chronic myeloid leukaemiaRadotinib DihydrochloridePhiladelphia chromosomeRadotinib DihydrochlorideChronic-phase myeloid leukaemiaRadotinib DihydrochlorideMyeloid leukaemiaRadotinib DihydrochlorideParkinson's diseaseRadotinib DihydrochlorideLeukaemiaRadotinib Dihydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Radotinib Dihydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
ethyl 3-amino-4-methylbenzoate→ethyl 3-guanidino-4-methylbenzoate nitrate→(E)-3-(dimethylamino)-1-(pyrazin-2-yl)prop-2-en-1-one→ethyl 4-methyl-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzoate→4-methyl-3-((4-(pyrazin-2-yl)pyrimidin-2-yl)amino)benzoic acid→3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline→3-bromo-5-(trifluoromethyl)aniline→4-methyl-1H-imidazole
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.